Lexicon Stresses Path Forward In Neuropathic Pain Despite Phase II PHN Disappointment
Shares Down By 8%
Executive Summary
The US firm’s AAK1 inhibitor asset missed the mark in a Phase II shingles-related pain trial but it appears unfazed as an earlier success in diabetes-related pain has a secured a path forward in the neuropathy space.